| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Executive Chairman | Director
2 companies
Iain D. Dukes is Chief Executive Officer at TRAW, with reported holdings spanning 2 companies. Iain D. Dukes's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $529K at current prices.
Iain D. Dukes's largest disclosed position is in IOVA as Director, worth about $477K. Net of sales, the IOVA filings show accumulation of 54,000 shares.
Iain D. Dukes has 25 Form 4 filings on record from August 2016 to July 2026, across 3 companies: Chief Executive Officer at Traws Pharma (TRAW), 2024–2026; Director at Iovance Biotherapeutics (IOVA), 2016–2026; Director at ImageneBio (IMA), 2021–2024.
The 31 reported transactions were 24 option or other derivative awards, 4 stock awards and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $458K and no sales.
The largest open-market purchase was 32,000 shares of IOVA at an average $9.15 on February 20, 2024, about $293K. Twelve months later IOVA was down 53%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 32,000 | $9.15 | $292,800.00 | +145.5% | -14.0% | -53.0% | |
| Nov 23, 2022 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 10,000 | $6.10 | $61,000.00 | +83.3% | +13.0% | -6.9% | |
| Dec 18, 2018 | IOVA Iovance Biotherapeutics, Inc. | Director | Buy | 12,000 | $8.65 | $103,796.40 | New | - | - |